Structure Therapeutics (GPCR) Projected to Announce Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Structure Therapeutics to post earnings of ($0.3250) per share and revenue of $50.00 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, analysts expect Structure Therapeutics to post ($1.87) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

Structure Therapeutics Stock Down 0.3%

Shares of GPCR opened at $21.48 on Thursday. Structure Therapeutics has a 12-month low of $20.50 and a 12-month high of $94.90. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -21.48 and a beta of -1.30. The stock’s 50-day moving average price is $34.65 and its 200 day moving average price is $49.91.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of research reports. Weiss Ratings downgraded Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 23rd. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Finally, Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.